Research graph
References from Long‐term effects of tofogliflozin on renal function in patients with type 2 diabetes: A retrospective multicenter study. Local targets link to admitted publications; unresolved targets remain external evidence.
Clinical manifestations of kidney disease among US adults with diabetes, 1988–2014
10.1001/jama.2016.10924 · 2016 · External reference
Canagliflozin and renal outcomes in type 2 diabetes and nephropathy
10.1056/nejmoa1811744 · 2019 · External reference
Empagliflozin in patients with chronic kidney disease
10.1056/nejmoa2204233 · 2023 · External reference
Dapagliflozin in patients with chronic kidney disease
10.1056/nejmoa2024816 · 2020 · External reference
Pharmacokinetics and pharmacodynamics of tofogliflozin (a selective SGLT2 inhibitor) in healthy male subjects
10.1055/s-0043-104779 · 2017 · External reference
SGLT2 inhibitors in the pipeline for the treatment of diabetes mellitus in Japan
10.1080/14656566.2016.1232395 · 2016 · External reference
Multicenter, open label, randomized controlled superiority trial for availability to reduce nocturnal urination frequency: The TOP‐STAR study
10.1111/jdi.14314 · 2024 · External reference
Changes in the estimated glomerular filtration rate and predictors of the renal prognosis in Japanese patients with type 2 diabetes: A retrospective study during the 12 months after the initiation of tofogliflozin
10.1371/journal.pone.0292014 · 2023 · External reference
Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function
10.1161/circulationaha.118.035901 · 2018 · External reference
Effects of dapagliflozin in stage 4 chronic kidney disease
10.1681/asn.2021020167 · 2021 · External reference
Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus treated in real‐world clinical practice: Results of a 36‐month post‐marketing surveillance study (J‐STEP/LT)
10.1111/jdi.13333 · 2021 · External reference
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
10.1056/nejmoa1504720 · 2015 · External reference
The sodium‐glucose cotransporter 2 inhibitor tofogliflozin prevents diabetic kidney disease progression in type 2 diabetic mice
10.1002/2211-5463.13014 · 2020 · External reference
Tofogliflozin, a novel sodium‐glucose co‐transporter 2 inhibitor, improves renal and pancreatic function in db/db mice
10.1111/bph.12269 · 2013 · External reference
The effect of sodium‐glucose cotransporter 2 inhibitor (tofogliflozin) on renal tubular damage in diabetic patients without albuminuria
10.1007/s11255-021-03064-6 · 2022 · External reference
Effects of sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, on the indices of renal tubular function in patients with type 2 diabetes
10.1002/edm2.15 · 2018 · External reference
Tofogliflozin, a highly selective inhibitor of SGLT2 blocks proinflammatory and proapoptotic effects of glucose overload on proximal tubular cells partly by suppressing oxidative stress generation
2016 · External reference
Clinical manifestations of kidney disease among US adults with diabetes, 1988–2014
10.1001/jama.2016.10924 · ExternalCitation · doi-reference
The sodium‐glucose cotransporter 2 inhibitor tofogliflozin prevents diabetic kidney disease progression in type 2 diabetic mice
10.1002/2211-5463.13014 · ExternalCitation · doi-reference
Effects of sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, on the indices of renal tubular function in patients with type 2 diabetes
10.1002/edm2.15 · ExternalCitation · doi-reference
The effect of sodium‐glucose cotransporter 2 inhibitor (tofogliflozin) on renal tubular damage in diabetic patients without albuminuria
10.1007/s11255-021-03064-6 · ExternalCitation · doi-reference
Pharmacokinetics and pharmacodynamics of tofogliflozin (a selective SGLT2 inhibitor) in healthy male subjects
10.1055/s-0043-104779 · ExternalCitation · doi-reference
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
10.1056/nejmoa1504720 · ExternalCitation · doi-reference
Canagliflozin and renal outcomes in type 2 diabetes and nephropathy
10.1056/nejmoa1811744 · ExternalCitation · doi-reference
Dapagliflozin in patients with chronic kidney disease
10.1056/nejmoa2024816 · ExternalCitation · doi-reference
Empagliflozin in patients with chronic kidney disease
10.1056/nejmoa2204233 · ExternalCitation · doi-reference
SGLT2 inhibitors in the pipeline for the treatment of diabetes mellitus in Japan
10.1080/14656566.2016.1232395 · ExternalCitation · doi-reference
Tofogliflozin, a novel sodium‐glucose co‐transporter 2 inhibitor, improves renal and pancreatic function in db/db mice
10.1111/bph.12269 · ExternalCitation · doi-reference
Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus treated in real‐world clinical practice: Results of a 36‐month post‐marketing surveillance study (J‐STEP/LT)
10.1111/jdi.13333 · ExternalCitation · doi-reference
Multicenter, open label, randomized controlled superiority trial for availability to reduce nocturnal urination frequency: The TOP‐STAR study
10.1111/jdi.14314 · ExternalCitation · doi-reference
Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function
10.1161/circulationaha.118.035901 · ExternalCitation · doi-reference
Changes in the estimated glomerular filtration rate and predictors of the renal prognosis in Japanese patients with type 2 diabetes: A retrospective study during the 12 months after the initiation of tofogliflozin
10.1371/journal.pone.0292014 · ExternalCitation · doi-reference
Effects of dapagliflozin in stage 4 chronic kidney disease
10.1681/asn.2021020167 · ExternalCitation · doi-reference
